Collegium Pharmaceutical, Inc. COLL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s accounts receivable?
- Collegium Pharmaceutical, Inc. (COLL) reported accounts receivable of $228.76M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s accounts receivable changed year-over-year?
- Collegium Pharmaceutical, Inc.'s accounts receivable increased by 0.0% year-over-year, from $228.71M to $228.76M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s accounts receivable has grown at a 20.5% compound annual growth rate (CAGR), from $83.32M to $211.33M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.